Combination therapy with Myocet and Herceptin safe and effective in advanced breast cancer Dec. 14, 2001
Orphan drug status awarded to bryostatin 1 for combination therapy of esophageal cancer Dec. 14, 2001
Repifermin continues to show excellent safety profile in phase II trials for various indications Dec. 13, 2001
NC-381 shows potential inhibitory effects on prostate tumor growth in preclinical studies Dec. 13, 2001
RSS